PT  - JOURNAL ARTICLE
ED  - ,
TI  - Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
AID  - 10.1136/jitc-2020-001806corr1
DP  - 2021 Nov 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e001806corr1
VI  - 9
IP  - 11
4099  - http://jitc.bmj.com/content/9/11/e001806corr1.short
4100  - http://jitc.bmj.com/content/9/11/e001806corr1.full
SO  - J Immunother Cancer2021 Nov 01; 9